News
-
Lorus Therapeutics Announces Successful Dose Escalation Of Its Phase I Clinical Trial Of LOR-253 And Initiation Of A Biomarker Clinical Study In Cancer Patients
1/7/2013
Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer, today announced that its Phase I clinical study of LOR-253 has successfully escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity.
-
Theravance Announces Initiation Of Phase 2b Study With Its LAMA Candidate, TD-4208, For The Treatment Of COPD
12/11/2012
Theravance, Inc. (NASDAQ: THRX) announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD.
-
Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, In Patients With Epilepsy
12/3/2012
Upsher-Smith Laboratories, Inc., (Upsher-Smith) announced that Phase I data for USL261 (intranasal midazolam) in patients with epilepsy were presented at the American Epilepsy Society Annual Meeting in San Diego, CA.
-
Phase 2b Data Of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved In Up To 85% Of Treatment-Naive Patients
11/10/2012
Final Phase 2b data from Boehringer Ingelheim's interferon (IFN)-free Phase 2b SOUND-C2 study showed that up to 85 percent of genotype 1b (GT1b) hepatitis C (HCV) patients achieved sustained virologic response (SVR or viral cure) 12 and 24 weeks after the end of treatment with the investigational treatment regimen of faldaprevir (BI 201335) and BI 207127, in combination with ribavirin (RBV)
-
Zafgen Announces Initiation Of Phase 2a Clinical Development With Beloranib In Obesity
11/6/2012
Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has initiated Phase 2a clinical testing of beloranib.
-
Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
11/1/2012
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 1b/2a study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).
-
Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial Of APD811 For Pulmonary Arterial Hypertension
10/12/2012
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).
-
FDA Inspects MicroConstants For Compliance With Good Laboratory Practices, No Deficiencies Noted
10/9/2012
Bioanalytical and pharmacokinetic specialty Contract Research Organization (CRO) MicroConstants announced today the successful completion of a five-day inspection by the United States Food and Drug Administration (FDA) for compliance with Good Laboratory Practice (GLP) regulations.
-
Dr. Brad Vince Of Vince & Associates Clinical Research Announces Award Of Nearly $10M Contract From The National Institute On Drug Abuse
9/19/2012
Vince & Associates Clinical Research announced it has been awarded a contract with the National Institute on Drug Abuse, part of the National Institutes of Health (NIH), to carry out clinical pharmacology studies to determine the pharmacokinetics and pharmacodynamics of new medication in humans.
-
Quotient And Pulmatrix Announce Completion Of Innovative COPD Proof-Of-Concept Clinical Program
9/4/2012
Quotient Clinical, a leading provider of specialist early stage drug development services, and Pulmatrix, a clinical stage biotechnology company creating novel inhaled therapeutics, recently announced the completion of an early clinical program to achieve proof-of-concept data in COPD patients for PUR118, Pulmatrix’s lead iCALM (inhaled dry powder cationic airway lining modulator) therapeutic.